<DOC>
	<DOCNO>NCT01509755</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial establish dose response relationship glycaemic control five dose level NNC90-1170 .</brief_summary>
	<brief_title>Comparison Liraglutide Glimepiride Blood Sugar Control Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects type 2 diabetes Duration diabetes least 3 month Both diet treated patient therapy OHA ( oral hypoglycemic agent ) Body Mass Index maximum 40 kg/m^2 HbA1c base analysis central laboratory : Between 7.510.0 % , inclusive , diet treat , maximum 9.0 % OHA treat Liver renal disease Cardiac problem Uncontrolled treated/untreated hypertension Proliferative retinopathy Recurrent severe hypoglycaemia judged Investigator Known suspect allergy trial product relate product Use drug ( except OHAs ) Investigator 's opinion could interfere blood glucose level</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>